# Amgen operating income entity: /record/amgen.md predicate: operating_income page: /record/amgen/operating_income as_of: 2026-11-09 cite: AsOf. "Amgen quarterly operating income: 3,710,000,000 United States dollar", as of 2026-09-30. Claim clm_B7EB0BB6DBEB, https://asof.is/claim/clm_B7EB0BB6DBEB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm. As of November 9, 2026, the latest operating income figure on the AsOf record for Amgen is $3.71 billion for the quarter ended September 30, 2026, from a primary source (sec.gov). Amgen's latest full-year operating income is $9.08 billion, dated December 31, 2025, from a primary source (sec.gov); the two periods are kept apart, never compared. 19 claims on Amgen's operating income, 1 open and 18 superseded, each dated and sourced; a replaced value is closed with an end date, never deleted. ## Latest operating income The newest figure for a shorter period, the quarter ended September 30, 2026: a quarterly_operating_income claim, kept apart from the full-year series. - [Amgen](/record/amgen.md) | quarterly_operating_income | 3,710,000,000 United States dollar | valid 2026-09-30 to present | conf 0.95 | valid | [clm_B7EB0BB6DBEB](/claim/clm_B7EB0BB6DBEB.md) sources: https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm ## Latest full-year operating income What the record asserts on 2026-11-09. - [Amgen](/record/amgen.md) | operating_income | 9,080,000,000 United States dollar | valid 2025-12-31 to present | conf 0.95 | valid | [clm_92AC0DE5846F](/claim/clm_92AC0DE5846F.md) sources: https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/0000318154-26-000010-index.htm ## Every dated value One claim per line, oldest first. Superseded claims stay visible. - [Amgen](/record/amgen.md) | operating_income | 3,980,000,000 United States dollar | valid 2007-12-31 to 2008-12-31 | conf 0.95 | superseded | superseded_by [clm_3327385ED8BC](/claim/clm_3327385ED8BC.md) | [clm_812C4678103A](/claim/clm_812C4678103A.md) sources: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm - [Amgen](/record/amgen.md) | operating_income | 5,214,000,000 United States dollar | valid 2008-12-31 to 2009-12-31 | conf 0.95 | superseded | superseded_by [clm_46A559E6C041](/claim/clm_46A559E6C041.md) | [clm_3327385ED8BC](/claim/clm_3327385ED8BC.md) sources: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm - [Amgen](/record/amgen.md) | operating_income | 5,506,000,000 United States dollar | valid 2009-12-31 to 2010-12-31 | conf 0.95 | superseded | superseded_by [clm_2282EE661302](/claim/clm_2282EE661302.md) | [clm_46A559E6C041](/claim/clm_46A559E6C041.md) sources: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm - [Amgen](/record/amgen.md) | operating_income | 5,545,000,000 United States dollar | valid 2010-12-31 to 2011-12-31 | conf 0.95 | superseded | superseded_by [clm_E05A3DDD94DD](/claim/clm_E05A3DDD94DD.md) | [clm_2282EE661302](/claim/clm_2282EE661302.md) sources: https://www.sec.gov/Archives/edgar/data/318154/000095012311018800/0000950123-11-018800-index.htm - [Amgen](/record/amgen.md) | operating_income | 4,312,000,000 United States dollar | valid 2011-12-31 to 2012-12-31 | conf 0.95 | superseded | superseded_by [clm_18B2DC42BBCB](/claim/clm_18B2DC42BBCB.md) | [clm_E05A3DDD94DD](/claim/clm_E05A3DDD94DD.md) sources: https://www.sec.gov/Archives/edgar/data/318154/000119312512086670/0001193125-12-086670-index.htm - [Amgen](/record/amgen.md) | operating_income | 5,577,000,000 United States dollar | valid 2012-12-31 to 2013-12-31 | conf 0.95 | superseded | superseded_by [clm_D1F7CCF21F2B](/claim/clm_D1F7CCF21F2B.md) | [clm_18B2DC42BBCB](/claim/clm_18B2DC42BBCB.md) sources: https://www.sec.gov/Archives/edgar/data/318154/000144530513000364/0001445305-13-000364-index.htm - [Amgen](/record/amgen.md) | operating_income | 5,867,000,000 United States dollar | valid 2013-12-31 to 2014-12-31 | conf 0.95 | superseded | superseded_by [clm_7FEB7D7DF8E7](/claim/clm_7FEB7D7DF8E7.md) | [clm_D1F7CCF21F2B](/claim/clm_D1F7CCF21F2B.md) sources: https://www.sec.gov/Archives/edgar/data/318154/000031815414000004/0000318154-14-000004-index.htm - [Amgen](/record/amgen.md) | operating_income | 6,191,000,000 United States dollar | valid 2014-12-31 to 2015-12-31 | conf 0.95 | superseded | superseded_by [clm_5F24CA9F1236](/claim/clm_5F24CA9F1236.md) | [clm_7FEB7D7DF8E7](/claim/clm_7FEB7D7DF8E7.md) sources: https://www.sec.gov/Archives/edgar/data/318154/000031815415000005/0000318154-15-000005-index.htm - [Amgen](/record/amgen.md) | operating_income | 8,470,000,000 United States dollar | valid 2015-12-31 to 2016-12-31 | conf 0.95 | superseded | superseded_by [clm_9C393580212E](/claim/clm_9C393580212E.md) | [clm_5F24CA9F1236](/claim/clm_5F24CA9F1236.md) sources: https://www.sec.gov/Archives/edgar/data/318154/000031815416000031/0000318154-16-000031-index.htm - [Amgen](/record/amgen.md) | operating_income | 9,794,000,000 United States dollar | valid 2016-12-31 to 2017-12-31 | conf 0.95 | superseded | superseded_by [clm_3FE1CD809E20](/claim/clm_3FE1CD809E20.md) | [clm_9C393580212E](/claim/clm_9C393580212E.md) sources: https://www.sec.gov/Archives/edgar/data/318154/000031815417000004/0000318154-17-000004-index.htm - [Amgen](/record/amgen.md) | operating_income | 9,973,000,000 United States dollar | valid 2017-12-31 to 2018-12-31 | conf 0.95 | superseded | superseded_by [clm_1E3D48FD1C81](/claim/clm_1E3D48FD1C81.md) | [clm_3FE1CD809E20](/claim/clm_3FE1CD809E20.md) sources: https://www.sec.gov/Archives/edgar/data/318154/000031815418000004/0000318154-18-000004-index.htm - [Amgen](/record/amgen.md) | operating_income | 10,263,000,000 United States dollar | valid 2018-12-31 to 2019-12-31 | conf 0.95 | superseded | superseded_by [clm_10BA888AB580](/claim/clm_10BA888AB580.md) | [clm_1E3D48FD1C81](/claim/clm_1E3D48FD1C81.md) sources: https://www.sec.gov/Archives/edgar/data/318154/000031815419000008/0000318154-19-000008-index.htm - [Amgen](/record/amgen.md) | operating_income | 9,674,000,000 United States dollar | valid 2019-12-31 to 2020-12-31 | conf 0.95 | superseded | superseded_by [clm_926C65AE4F09](/claim/clm_926C65AE4F09.md) | [clm_10BA888AB580](/claim/clm_10BA888AB580.md) sources: https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/0000318154-20-000017-index.htm - [Amgen](/record/amgen.md) | operating_income | 9,139,000,000 United States dollar | valid 2020-12-31 to 2021-12-31 | conf 0.95 | superseded | superseded_by [clm_018B07550FF4](/claim/clm_018B07550FF4.md) | [clm_926C65AE4F09](/claim/clm_926C65AE4F09.md) sources: https://www.sec.gov/Archives/edgar/data/318154/000031815421000010/0000318154-21-000010-index.htm - [Amgen](/record/amgen.md) | operating_income | 7,639,000,000 United States dollar | valid 2021-12-31 to 2022-12-31 | conf 0.95 | superseded | superseded_by [clm_0207ECA7A000](/claim/clm_0207ECA7A000.md) | [clm_018B07550FF4](/claim/clm_018B07550FF4.md) sources: https://www.sec.gov/Archives/edgar/data/318154/000031815422000010/0000318154-22-000010-index.htm - [Amgen](/record/amgen.md) | operating_income | 9,566,000,000 United States dollar | valid 2022-12-31 to 2023-12-31 | conf 0.95 | superseded | superseded_by [clm_D213C7365716](/claim/clm_D213C7365716.md) | [clm_0207ECA7A000](/claim/clm_0207ECA7A000.md) sources: https://www.sec.gov/Archives/edgar/data/318154/000031815423000017/0000318154-23-000017-index.htm - [Amgen](/record/amgen.md) | operating_income | 7,897,000,000 United States dollar | valid 2023-12-31 to 2024-12-31 | conf 0.95 | superseded | superseded_by [clm_14D79C128253](/claim/clm_14D79C128253.md) | [clm_D213C7365716](/claim/clm_D213C7365716.md) sources: https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/0000318154-24-000011-index.htm - [Amgen](/record/amgen.md) | operating_income | 7,258,000,000 United States dollar | valid 2024-12-31 to 2025-12-31 | conf 0.95 | superseded | superseded_by [clm_92AC0DE5846F](/claim/clm_92AC0DE5846F.md) | [clm_14D79C128253](/claim/clm_14D79C128253.md) sources: https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/0000318154-25-000010-index.htm - [Amgen](/record/amgen.md) | operating_income | 9,080,000,000 United States dollar | valid 2025-12-31 to present | conf 0.95 | valid | [clm_92AC0DE5846F](/claim/clm_92AC0DE5846F.md) sources: https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/0000318154-26-000010-index.htm ## What replaced what - $3.98 billion (2007-12-31 to 2008-12-31, [clm_812C4678103A](/claim/clm_812C4678103A.md)) was replaced by $5.21 billion from 2008-12-31 ([clm_3327385ED8BC](/claim/clm_3327385ED8BC.md)) - $5.21 billion (2008-12-31 to 2009-12-31, [clm_3327385ED8BC](/claim/clm_3327385ED8BC.md)) was replaced by $5.51 billion from 2009-12-31 ([clm_46A559E6C041](/claim/clm_46A559E6C041.md)) - $5.51 billion (2009-12-31 to 2010-12-31, [clm_46A559E6C041](/claim/clm_46A559E6C041.md)) was replaced by $5.55 billion from 2010-12-31 ([clm_2282EE661302](/claim/clm_2282EE661302.md)) - $5.55 billion (2010-12-31 to 2011-12-31, [clm_2282EE661302](/claim/clm_2282EE661302.md)) was replaced by $4.31 billion from 2011-12-31 ([clm_E05A3DDD94DD](/claim/clm_E05A3DDD94DD.md)) - $4.31 billion (2011-12-31 to 2012-12-31, [clm_E05A3DDD94DD](/claim/clm_E05A3DDD94DD.md)) was replaced by $5.58 billion from 2012-12-31 ([clm_18B2DC42BBCB](/claim/clm_18B2DC42BBCB.md)) - $5.58 billion (2012-12-31 to 2013-12-31, [clm_18B2DC42BBCB](/claim/clm_18B2DC42BBCB.md)) was replaced by $5.87 billion from 2013-12-31 ([clm_D1F7CCF21F2B](/claim/clm_D1F7CCF21F2B.md)) - $5.87 billion (2013-12-31 to 2014-12-31, [clm_D1F7CCF21F2B](/claim/clm_D1F7CCF21F2B.md)) was replaced by $6.19 billion from 2014-12-31 ([clm_7FEB7D7DF8E7](/claim/clm_7FEB7D7DF8E7.md)) - $6.19 billion (2014-12-31 to 2015-12-31, [clm_7FEB7D7DF8E7](/claim/clm_7FEB7D7DF8E7.md)) was replaced by $8.47 billion from 2015-12-31 ([clm_5F24CA9F1236](/claim/clm_5F24CA9F1236.md)) - $8.47 billion (2015-12-31 to 2016-12-31, [clm_5F24CA9F1236](/claim/clm_5F24CA9F1236.md)) was replaced by $9.79 billion from 2016-12-31 ([clm_9C393580212E](/claim/clm_9C393580212E.md)) - $9.79 billion (2016-12-31 to 2017-12-31, [clm_9C393580212E](/claim/clm_9C393580212E.md)) was replaced by $9.97 billion from 2017-12-31 ([clm_3FE1CD809E20](/claim/clm_3FE1CD809E20.md)) - $9.97 billion (2017-12-31 to 2018-12-31, [clm_3FE1CD809E20](/claim/clm_3FE1CD809E20.md)) was replaced by $10.26 billion from 2018-12-31 ([clm_1E3D48FD1C81](/claim/clm_1E3D48FD1C81.md)) - $10.26 billion (2018-12-31 to 2019-12-31, [clm_1E3D48FD1C81](/claim/clm_1E3D48FD1C81.md)) was replaced by $9.67 billion from 2019-12-31 ([clm_10BA888AB580](/claim/clm_10BA888AB580.md)) - $9.67 billion (2019-12-31 to 2020-12-31, [clm_10BA888AB580](/claim/clm_10BA888AB580.md)) was replaced by $9.14 billion from 2020-12-31 ([clm_926C65AE4F09](/claim/clm_926C65AE4F09.md)) - $9.14 billion (2020-12-31 to 2021-12-31, [clm_926C65AE4F09](/claim/clm_926C65AE4F09.md)) was replaced by $7.64 billion from 2021-12-31 ([clm_018B07550FF4](/claim/clm_018B07550FF4.md)) - $7.64 billion (2021-12-31 to 2022-12-31, [clm_018B07550FF4](/claim/clm_018B07550FF4.md)) was replaced by $9.57 billion from 2022-12-31 ([clm_0207ECA7A000](/claim/clm_0207ECA7A000.md)) - $9.57 billion (2022-12-31 to 2023-12-31, [clm_0207ECA7A000](/claim/clm_0207ECA7A000.md)) was replaced by $7.9 billion from 2023-12-31 ([clm_D213C7365716](/claim/clm_D213C7365716.md)) - $7.9 billion (2023-12-31 to 2024-12-31, [clm_D213C7365716](/claim/clm_D213C7365716.md)) was replaced by $7.26 billion from 2024-12-31 ([clm_14D79C128253](/claim/clm_14D79C128253.md)) - $7.26 billion (2024-12-31 to 2025-12-31, [clm_14D79C128253](/claim/clm_14D79C128253.md)) was replaced by $9.08 billion from 2025-12-31 ([clm_92AC0DE5846F](/claim/clm_92AC0DE5846F.md)) ## Questions this record answers ### What is Amgen's current operating income? The latest figure on the record is $3.71 billion for the quarter ended September 30, 2026, from a primary source (sec.gov). The latest full-year figure is $9.08 billion, dated December 31, 2025, from a primary source (sec.gov). The record asserts both as of November 9, 2026. ### What was Amgen's operating income for the quarter ended September 30, 2026? $3.71 billion for the quarter ended September 30, 2026, dated September 30, 2026, from a primary source (sec.gov) (status valid, confidence 0.95). ### When did Amgen's operating income last change? The latest value on the record is $9.08 billion, dated December 31, 2025; before it the record holds $7.26 billion, dated December 31, 2024 and closed on December 31, 2025. ### What was Amgen's operating income before $9.08 billion? $7.26 billion, valid from December 31, 2024 to December 31, 2025 (status superseded), from a primary source (sec.gov). ## Read on - This page: /record/amgen/operating_income (markdown: /record/amgen/operating_income.md) - Entity twin: /record/amgen.md ยท timeline: /timelines/amgen.md --- AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.